Zacks Investment Research on MSN
Will Defencath continue to aid CorMedix's top line in Q4 earnings?
CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback